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WE have observed uncontrollable cardiogenic Tumour necrosis factor- and shock as a cardiovascular manifestation of
systemic inflammatory response syndrome (SIRS) adenosine in endotoxin shock-
leading to death in a 62-year-old woman. The
diagnosis of SIRS was based on the demonstration related cardiovascular symptoms
of endotoxinaemia, and highly elevated plasma
levels of turnout necrosis factor (TNF)-, and
interleukin (IL)-10. We suggest that these cyto- S. Sipka,’cA T. Seres, Z. Dinya,
3 Z. Szekanecz,
kines may contribute to the terminal SIRS-related J Szentmikl6si,
2 E. Bodolay and G. Szegedi arrythmias, impaired myocardial contractility, as
well as increased vascular permeability. In
addition, the increased production of adenosine, a
counter-regulatory mediator of inflammation, Third Department of Medicine and 2Department
may also play a role in cardiodepression. We of Pharmacology, University Mdical School, and
suggest a relationship between the action of TNF- 3Department of Orgaic Chemistry, Lajos Kossuth , IL-10 and adenosine in the pathogenesis of cir- University, Debrecen, Hungary
culatory symptoms described above.
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Introduction
A number of inflammatory mediators may be
involved in the pathogenesis of endotoxin-
induced systemic inflammatory response -
drome (SIRS). The most severe stage of SIRS is
fatigue and splenomegaly. The patient had pre-
viously been examined at a number of hospitals,
where increased erythrocyte sedimentation rate
and sideropenic anaemia with low iron binding
capacity were found. Other laboratory values
were normal. Several diagnostic tests had been the multiple organ dysfunction syndrome performed throughout the months without any (MODS), which affects, among others, the direct evidence for infectious, immunopathologi- cardiovascular system and this leads to death in
half of these patients.’2 The cascade of events in
SIRS may be triggered by endotoxin, which leads
to the activation of monocytes/macrophages.
These cells begin producing high amounts of
tumour necrosis factor (TNF)<z and interleukin
(It)-1; followed by the secretion of other media-
cal diseases or malignancies. However, we
observed a 38-39C fever and other clinical
symptoms of endotoxin shock, which in a few
days led {o severe generalized oedema together
with the signs of multiorgan failure (MODS).
This latter involved the lungs, the cardiovascular
tors, such as IL-6, IL-8, platelet-activating factor system, the kidneys and, terminally, the central
(PAF), leukotrienes, endothelin-1, and others. nervous system. All serial blood culture and ser-
ological tests were negative for bacteria, viruses TNF-z and IL-1 may also stimulate T cells to and fungi. However, the plasma level of endo- produce IL-2. Increasing amounts of data suggest toxin was increased (3.85 IU/ml) compared to a pathogenetic relationship between these media- normal plasma (< 1 IU/ml) as determined by the tors in SIRS-related symptoms. Adenosine is a Limulus assay (Biomondex, Budapest)(Table 1). well-known negative chronotropic, inotropic and
dromotropic agent
4 and its production by phago- In addition, the diagnosis of SIRS was also based
cytes can be stimulated by hypoxia
5-8 or other on the clinical and laboratory signs of MODS and
mediators, such as PAF.9 Thus, adenosine may
also be involved in SIRS.
10-11 By presenting a
case history, we wished to demonstrate the pos-
sible pathogenetic role of certain cytokines, such
as TNF-0t and IL-10, as well as the counter-reg-
ulatory mediator adenosine in the cardiovascular
events underlying SIRS.
Case histow
A 62-year-old woman was admitted to our
diffuse intravascular coagulation. Immunological
laboratory techniques showed complement acti-
vation, higher IgM level and decreased in vitro
chemotaxis of neutrophils and monocytes. Term-
inally, the patient had impaired myocardial con-
tractility associated with atrial fibrillation,
catecholamine-resistant cardiogenic shock and
died of asystolia. Autopsy showed the hypoxic
damage of most organs, again with no macro-
scopic signs of tumours or inflammation.
Plasma samples were taken from the patient 1
institution with a 1-year history of fever, anaemia, day before her death. This was the time when
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Table 1. Cytokine and adenosine levels in plasma
Sample Reference
TNF- 126 pg/ml < 15.7 pg/ml
IL-2 N.D.* < 31.3 pg/ml
IL-10 250 pg/ml < 15.6 pg/ml
Adenosine O.75 lmol/I < 0.12 lmol/I
Endotoxin 3.85 IU/ml < IU/ml
*N.D. Non-detectable.
the most serious cardiovascular events described
above, as well as generalized oedema were
observed. Samples were assayed for TNF-a, IL-2
(Amersham) and IL-10 (Biosource) using ELISA
systems. Plasma adenosine concentration was
determined by mass spectroscopy.
4 Results are
given in Table 1. IL-10, TNF-a and adenosine
showed striking 16-, 8- and 6-fold increases
above the indicated reference level (normal con-
trois), respectively. In contrast, we could not
detect any IL-2 in the plasma.
The enormously high amount of plasma IL-10
measured could be secreted mainly by Th2 type
T cells and it could take part in processes sup-
pressing TNF-a and IL-2 production. The
reduction of TNF-a production is a mode of
action of IL-10 that diminishes mortality to lethal
endotoxinaemia in mice.
14
Our concept, suggesting the role of certain
cytokines in endotoxin shock-related heart
failure, may help to explain some aspects of
cardiac mortality in SIRS. However, other inflam-
matory mediators, such as adenosine may also
regulate the action of these cytokines. At the
same time they may act independently from cyto-
kines and directly cause cardiodepression, in
addition, we suggest that TNF-a Or adenosine
antagonists, such as pentoxifylline or theophyl-
line, respectively, may be used in the therapy of
SIRS and the related MODS. Future therapeutic
tools may include monoclonal antibodies raised
against these mediators or antiinflammatory cyto-
kines, such as IL-10.14
Discussion
The high amount of TNF-a found in our
patient’s plasma may be important in the patho-
logic regulation underlying SIRS as it is the first
mediator showing increased production by mac-
rophages. As TNF-a itself may cause endothelial
injury and leak, systemic vasodilatation, and
decreases in myocardial contractility, it may, at
least in part, be responsible for the impaired
myocardial function and generalized oedema.
TNF-a stimulates the production of IL-1, IL-6, IL-8
and PAF, as well as the metabolism of arachi-
donic acid. Among these mediators leukotrienes
and PAF may act in concert with endotoxin and
TNF-a in increasing capillary permeability. In the
case of our patient, therapy included pentox-
yphylline and high-dose glucocorticoids, drugs
known to suppress cytokine production.
Although no fever was observed in the last week
prior to death, probably due to the effects of this
combined treatment, TNF-a production could
not be totally inhibited, which resulted in the
further perpetuation of SIRS and death.
Elevated adenosine levels were also found in
our patient’s plasma. As described above, adeno-
sine production can be induced by hypoxia,5-u
as well as PAF or LTB4,9 pathogenetic factors
also important in the pathogenesis of SIRS. Ade-
nosine can also act as a counter-regulatory med-
iator by inhibiting the production of TNF-a.
2 Its
negative effects on the myocardium described
above,
4 however, can be fatal under certain con-
ditions, as it was in the case of our patient.
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